Журнал включен в российские и международные библиотечные и реферативные базы данных
РИНЦ (Россия)
RINZ (RUSSIA)
Регистрационное агентство DOI (США)
DOI Registration Agency (USA)
Эко-Вектор (Россия)
Eco-Vector (Russia)
Ulrichsweb (Ulrich’s Periodicals Director

Noninvasive biomarkers in the diagnosis of nonalcoholic fatty liver disease

DOI: https://doi.org/10.29296/25879979-2023-04-06
Issue: 
4
Year: 
2023

O.P. Dudanova
Federal State Budgetary Educational Institution of Higher Education «Petrozavodsk State University», 33 Lenina av., Petrozavodsk, 185910, e-mail: [email protected]

This article presents information about traditional and proprietary fibrosis and steatosis scales in nonalcoholic fatty liver disease (NAFLD): NAFLD fibrosis score, BARD, FIB-4, APRIL, FLI, HSI, LAP, and others. Noninvasive methods of NAFLD recognition have a number of advantages over histological examination of liver biopsy specimens and instrumental methods – ultrasound and magnetic resonance elastography. They contain simple, accessible and inexpensive clinical and laboratory parameters that allow estimating the severity of NAFLD and predictors of its unfavorable course. Domestic and foreign authors proved a close association of these scales with morphological and sonographic signs of NAFLD. These fibrosis and steatosis scales are recommended for use as first-line diagnosis in primary care settings for population-based studies.
Keywords: 
noninvasive fibrosis scores
steatosis scores
nonalcoholic fatty liver disease
nursing practice.

References: 
  1. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(4): 104–140. DOI https://doi.org/10.22416/1382-4376-2022-32-4-104-140
  2. Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185(1): 4–52. DOI: 10.31146/1682-8658-ecg-185-1-4-52
  3. Younossi ZM, Golabi P, Paik JM et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4): 1335–1347. doi: 10.1097/HEP.0000000000000004.
  4. Селиверстов П.В., Джадхав С.Н., Цурцумия Д.Б. и др. Неалкогольная жировая болезнь печени: возможности диагностики. РМЖ. 2019; 5: 36–40.
  5. Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4): 846–854. doi: 10.1002/hep.21496. PMID: 17393509.
  6. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57(10): 1441–1447. doi: 10.1136/gut.2007.146019.
  7. Sterling RK, Lissen E, Clumeck N. et al. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6): 1317–1325. doi: 10.1002/hep.21178. PMID: 16729309.
  8. Lin ZH, Xin YN, Dong QJ. Et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3): 726–736. doi: 10.1002/hep.24105.
  9. Маршалко Д.В., Пчелин И.Ю., Шишкин А.Н. Неалкогольная жировая болезнь печени: коморбидность, клиническое значение и методы диагностики фиброза печени. Juvenis scientia. 2018; 2:14–17. – EDN YSMDUQ.
  10. Шичкин М.Ф., Жирков И.И. Неинвазивные методы диагностики неалкогольной жировой печени у военнослужащих. Известия Российской военно-медицинской академии. 2022; 41 (S2): 461–464. – EDN UNPRVQ.
  11. Пархоменко Л.К., Страшок Л.А., Хоменко М.А. Особенности использования неинвазивных тестов оценки фиброза печени у подростков с ожирением. Здоровье ребенка. 2019; 14 (S1): 72–76. DOI 10.22141/2224-0551.14.0.2019.165523. – EDN ZQYZID.
  12. Akpoigbe K, Bath K, Genao A, Culpepper-Morgan J. Performance of Non-invasive Biomarkers of Liver Fibrosis Amongst Hispanics and African Americans. Cureus. 2023; 15(2): e35032. doi: 10.7759/cureus.35032.
  13. Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol. 2021; 21(1): 453. doi: 10.1186/s12876-021-02038-3.
  14. McPherson S, Hardy T, Dufour JF. et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017; 112(5): 740–751. doi: 10.1038/ajg.2016.453.
  15. Adams LA, Bulsara M, Rossi E. et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51(10): 1867–1873. doi: 10.1373/clinchem.2005.048389.
  16. Tada T, Kumada T., Hidenori Toyoda H. et al. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease, Biomarkers. 2018; 23(4): 328–334, DOI: 10.1080/1354750X.2018.1425915
  17. Bedogni G, Bellentani S, Miglioli L. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33.
  18. Носов А.Е., Зенина М.Т., Горбушина О.Ю. и др. Значимость клинико-лабораторных индексов в диагностике неалкогольной жировой болезни печени. Терапевтический архив. 2021; 93 (8): 883–889. DOI: 10.26442/00403660.2021.08.200973.
  19. Lee JH, Kim D, Kim HJ. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42(7): 503–508. doi: 10.1016/j.dld.2009.08.002/.
  20. Wu P, Wang Y, Ye Y. et al. Liver biomarkers, lipid metabolites, and risk of gestational diabetes mellitus in a prospective study among Chinese pregnant women. BMC Med. 2023; 21(1): 150. doi: 10.1186/s12916-023-02818-6.
  21. Ebrahimi M, Seyedi SA, Nabipoorashrafi SA. et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 2023 15;22(1): 41. doi: 10.1186/s12944-023-01802-6.